Table 4 Adverse events

From: Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

 

Regardless of attribution

At least possibly Related

Evaluable

48

48

Grade 3+

38 (79%)

36 (75%)

Grade 4+

6 (13%)

6 (13%)

Grade 5

0 (0%)

0 (0%)

Grade 3+ hematologic

34 (71%)

33 (69%)

Grade 4+ hematologic

6 (13%)

6 (13%)

Grade 3+ non-hematologic

13 (27%)

11 (23%)

Grade 4+ non-hematologic

2 (4%)

1 (2%)

Back to article page